In a phase 0 clinical trial with 8 patients, including 6 with SS, Zhang and colleagues showed that weekly treatment with interferon-γ (IFN-γ) increased PD-L1 expression (in tumor and myeloid cells), increased CD8+ T cell infiltrates, and upregulated tumor surface MHC-I expression.44 Here, CD274 is linked to neoplasm.